Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Wolfgang Miesbach: A Mim8 Extension Study by Pratima Chowdary’s Team Showing Robust Profile in Hemophilia A
Wolfgang Miesbach /LinkedIn
Oct 15, 2025, 05:56

Wolfgang Miesbach: A Mim8 Extension Study by Pratima Chowdary’s Team Showing Robust Profile in Hemophilia A

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

”Promising Long-term Safety Data: Mim8 Extension Study Demonstrates Robust Profile in Hemophilia A.

Great results from the FRONTIER1 Phase 1/2 Multiple Ascending Dose (MAD) extension study show exceptional long-term safety for Mim8 (denecimig) across 69.5 patient-years of exposure in 41 patients with severe hemophilia A.

Study Design and Population:
Phase 1/2 extension study (up to 148 weeks additional treatment)
Mean age: 33.1 years (range 14-64), including 6 adolescents
90.2% without inhibitors, 9.8% with inhibitors

Outstanding Safety Profile:
Exceptional injection tolerability: Only 0.2% injection-site reaction rate (6 reactions in 3,128 injections)
Zero anti-Mim8 antibodies detected throughout extension
No thromboembolic events observed

Only 2 patients discontinued:
– 1 due to Hodgkin lymphoma (unrelated to Mim8)
– 1 due to patient decision after sequence of joint bleeds
85.4% experienced mostly mild-moderate TEAEs (unrelated to treatment)

Clinical Efficacy:
67.7% of patients on weekly dosing achieved zero bleeds
88.9% of patients on monthly dosing achieved zero bleeds
Flexible dosing options: QW (6-11mg) OR Q4W (30-46mg)
Stable thrombin generation within target range (150-200 nM)

Superior Potency Confirmed:
Mim8 achieved comparable peak thrombin generation at approximately 15-fold lower plasma concentrations than emicizumab.

This refers to the actual drug concentration needed in blood plasma to achieve similar haemostatic effect.

Next Steps:
These compelling extension data support the ongoing Phase 3 FRONTIER2 (NCT05053139) and FRONTIER3 (NCT05306418) trials, plus the planned FRONTIER4 long-term study investigating biweekly dosing options.

Congratulations to Pratima Chowdary and the international research team on these results published in RPTH Journal.”

Read the full article in RPTH.

Article: FRONTIER1 multiple ascending dose extension: a safety, tolerability, pharmacokinetics, and pharmacodynamics study of Mim8 in patients with haemophilia A

Authors: Pratima Chowdary, Steven R. Lentz, Lidia Gil, Francisco J. López-Jaime, Jerzy Windyga, Wan Hui Ong Clausen, Peter Nørkjær Laursen, Johnny Mahlangu

Wolfgang Miesbach: A Mim8 Extension Study by Pratima Chowdary's Team Showing Robust Profile in Hemophilia A

Stay updated on all scientific advances in the field of hemophilia with Hemostasis Today.

bleeding disorders Emicizumab Francisco J. López-Jaime FRONTIER Health Hematology Hemophilia A Hemostasis Hemostasis Today Hodgkin lymphoma Jerzy Windyga Johnny Mahlangu Lidia Gil Medicine Mim8 Peter Nørkjær Laursen Pratima Chowdary RPTH Journal Steven R. Lentz Wan Hui Ong Clausen
NewsFeed